|
|||||
|
|
||||||
Journal of Clinical Oncology, Vol 25, No 16 (June 1), 2007: pp. 2313-2321 © 2007 American Society of Clinical Oncology. DOI: 10.1200/JCO.2006.08.6900
Priorities in Colorectal Cancer Research: Recommendations From the Gastrointestinal Scientific Leadership Council of the Coalition of Cancer Cooperative Groups
From the Coalition of Cancer Cooperative Groups; University of Pennsylvania, Abramson Cancer Center, Philadelphia; Allegheny Cancer Center, Pittsburgh, PA; University of Colorado Health Sciences Center, Denver, CO; Mayo Clinic; Mayo Clinic Comprehensive Cancer Center, Rochester, MN; University of California, San Francisco; University of Southern California Norris Cancer Center, Los Angeles, CA; Vanderbilt-Ingram Cancer Center, Nashville, TN; University of North Carolina, Chapel Hill, NC; Mayo Clinic Scottsdale, Scottsdale, AZ; The University of Texas M.D. Anderson Cancer Center, Houston, TX; Helen F. Graham Cancer Center, Newark, DE; University of Chicago, Chicago, IL; and the Princess Margaret Hospital, Toronto, Canada Address reprint requests to Peter J. O'Dwyer, MD, University of Pennsylvania Cancer Center, 51 N 39th St, MAB-103, Philadelphia, PA 19104; email: peter.odwyer{at}uphs.upenn.edu Emerging technologies have greatly expanded our ability to detect, characterize, and treat colorectal cancer. The Coalition of Cancer Cooperative Groups convened a multidisciplinary panel, the Scientific Leadership Council in GI cancer, to discuss and advise on the priorities and opportunities to advance current and future approaches into the clinical arena to impact most rapidly the morbidity and mortality from this disease. The Council's recommendations for research priorities are the result of engagement of community and academic oncologists, patient advocacy groups, and other stakeholders including the pharmaceutical industry and governmental agencies. We detail some key prospects for investigation in the areas of colon cancer detection, prevention, and surgical and medical management. Many are in early or definitive clinical trials, and a focus on rapid accrual is urged. The implementation of biology-directed laboratory investigations, both in association with ongoing clinical trials and as a separate developmental strategy for targeted therapies, is supported as the route to individualized therapy. The Council held its initial meeting in Philadelphia, PA, on December 13-14, 2004. A follow-up Scientific Dialogue with representatives of oncology-focused pharmaceutical companies and the patient advocacy community was held in Dana Point, CA, on April 14-15, 2005. Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.
This article has been cited by other articles:
|
|||||||||||||
|
|||||||||||
|
Copyright © 2007 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
|